Humasis Terminates 92 Billion KRW COVID-19 Diagnostic Kit Contract with Celltrion

The Humasis COVID-19 self-test diagnostic kit, 'Humasis COVID-19 Home Test,' is being sold at a pharmacy in downtown Seoul on the 3rd. The self-test kit works by dropping a specimen collected directly from the nasal cavity into the kit to check for positive or negative results. Infection status can be visually confirmed within 15 to 30 minutes. If two red lines (control line C and test line T) appear on the kit, the result is positive. In this case, you must visit a screening clinic operated by the quarantine authorities to undergo the conventional test method, the polymerase chain reaction (PCR) test. Photo by Moon Honam munonam@

[Asia Economy Reporter Jang Hyowon] Humasis announced on the 29th that it has terminated the supply contract for COVID-19 antigen diagnostic home kits with Celltrion, valued at 91.9673 billion KRW. This amount corresponds to 201.16% of the consolidated sales at the end of 2020.

The initial contract was made on January 22. The total contract amount was 114.78 million USD (approximately 133.6 billion KRW). Of this, 37.522516 million USD was fulfilled according to the contract amount, and the remainder has now been terminated.

Since the initial contract date, Humasis's stock price surged. The closing price the day before the contract was 16,600 KRW, but it continued to rise after the contract, reaching as high as 36,450 KRW on February 3. This represents a 119% increase in just six trading days. However, based on the previous day's closing price, Humasis's stock price is around 15,200 KRW.

Humasis stated, "This contract termination is due to Celltrion's unilateral notice of contract termination," adding, "We are currently reviewing this matter legally and are preparing active responses, including legal action."

This content was produced with the assistance of AI translation services.